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ABSTRACT
Objective: In the present study, an attempt was made to develop polymeric blend transdermal patch of repaglinide using hydroxypropyl methyl 
cellulose (HPMC) K4M and kondagogu gum.
Methods: A series of repaglinide drug-incorporated HPMC K4M-kondagogu gum matrix films were prepared by solvent casting method. The prepared 
transdermal films were evaluated for various parameters such as thickness, tensile strength, folding endurance, % elongation, % moisture content, % 
moisture uptake, % drug content, in vitro drug release, and drug excipient compatibility.
Results: The Fourier-transform infrared spectra of the pure drug as well as drug-incorporated formulation indicated that no chemical interaction 
occurred between the drug and the polymers used. Differential scanning calorimetry thermograms of the pure drug and prepared formulation 
indicated that the drug has dispersed in micron level in the prepared films. In vitro release study data of prepared formulations were fitted into various 
mathematical models, and the best-fit model was found to be Higuchi model.
Conclusion: Among all the formulations studied, the formulation F4 was found to be an optimized composition for efficient transdermal delivery of 
repaglinide for 24 h study period. Stability studies of the drug formulations concluded that the drug was stable in the optimized formulation for the 
study period.
Keywords: Hydroxypropyl methyl cellulose K4M, Kondagogu gum, Transdermal film, Repaglinide.
INTRODUCTION
Natural polymers and their derivatives are used extensively to prepare 
various pharmaceutical dosage forms and novel drug delivery systems 
and thus can compete with synthetic polymeric materials which are 
widely utilized in the present market [1]. Natural polysaccharides hold 
several distinct advantages compared to synthetic polymeric materials 
as they are non-toxic, biodegradable, less expensive, and easily available.
Over the past few decades, natural biodegradable polysaccharides such 
as guar gum, chitosan, carrageenans, sodium alginate (Na-alginate), 
pectin, xanthan gum, gellan gum, and agar have been widely used [2,3]. 
These polymers can be used in various ways in the formulation of 
targeted and controlled drug delivery systems as they have different 
derivatizable groups, a wide range of molecular weight, and varying 
chemical composition. Transdermal drug delivery system has been 
showing an increased interest in the drug administration through the 
skin for both local therapeutic effects as well as for systemic delivery of 
drugs. Development of transdermal delivery system started in 1970s, 
and in 1979, the first transdermal patch of scopolamine was approved 
by the United States FDA for the treatment of motion sickness, and 
later, a nitroglycerine patch was marketed for the treatment of angina 
pectoris [4,5].
Fundamentally, thin films are good candidates for targeting sensitive 
site which may not be possible using tablets or liquid formulations. 
Transdermal films have shown the capabilities to improve the onset 
of drug action, reduce the dose frequency, and enhance the drug 
efficacy [6-9]. Similarly, transdermal films are useful for eliminating 
side effects of a particular drug and reducing extensive metabolism 
which is caused by proteolytic enzymes. Ideal films exhibit desirable 
features such as sufficient drug loading capacity, fast dissolution rate 
or long residence time at the site of administration, and acceptable 
formulation stability. They should also be non-toxic, biocompatible, and 
biodegradable [10,11].
Kondagugu gum (KG) is the dried exudate obtained from the tree 
Cochlospermum gossypium belonging to the family Bixaceae [12]. It is 
a high molecular weight complex acetylated polysaccharide consisting 
mainly of D-galacturonic acid, D-galactose, and L-rhamnose [13]. KG 
has demonstrated a lot of interest in the preparation of hydrophilic 
matrix tablets because of its properties such as high water swellability, 
nontoxicity, and low cost. Unlike other water-soluble gums, it does not 
dissolve in water but absorbs to form a viscous colloidal solution [14]. 
Powdered KG swells in cold water to an extent that a 3–4% sol will 
produce a gel of uniform smoothness and texture.
Kondagogu gum has also been used for biosorption of toxic heavy metals 
such as nickel and total chromium from aqueous solutions [15]. Gum 
kondagogu modified magnetic nano adsorbent has also been prepared 
for removing toxic metal ions from industrial effluents [16]. It was 
used as a carrier in preparing floating drug delivery system [17] and 
as a polyelectrolyte complex in combination with chitosan [18]. Even 
though KG is an important forest product, its commercial exploitation 
has been limited. Hydroxypropyl methyl cellulose (HPMC) K4M is a 
water-soluble cellulose derivative designed to perform many functions 
in pharmacy. It has a viscosity range of 2,700–5,040 cps and widely 
used in the formulation of films.
Diabetes mellitus is a major and growing health problem worldwide which 
is an important cause of prolonged ill-health and early death. It is a chronic 
metabolic disorder characterized by a high blood glucose concentration 
(hyperglycemia) caused by insulin deficiency, and it is often combined 
with insulin resistance [19]. Repaglinide is an oral blood glucose-lowering 
drug of the meglitinide class and used to treat non-insulin-dependent 
diabetes mellitus. It lowers blood glucose level by stimulating the release 
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of insulin from the pancreas. It has an extremely short half-life of 1 h. 
In addition, the oral bioavailability of repaglinide is low (56%) due to 
extensive hepatic first-pass metabolism. Dosage frequency of repaglinide 
is 0.5–4 mg and for 3–4 times in a day. It has melting point of 130–131°C 
and molecular weight 452.58. Topical preparation of repaglinide may be 
beneficial to the patient since it reduces adverse effects and avoids the 
hepatic first-pass metabolism [20-22].
In the present study, an attempt was made to develop polymeric blend 
transdermal patch of repaglinide using HPMC K4M and kondagogu gum. 
Different formulations were prepared by varying the concentration of 
gums, and the prepared films were evaluated.
MATERIALS AND METHODS
Materials
Repaglinide was received as gift sample from Lupin Limited, Goa, 
India. Kondagogu gum was purchased from Girijan Cooperative 
Society, Government of Andhra Pradesh, Hyderabad, India. HPMCK4M, 
polyethylene glycol 400, and propylene glycol were purchased from 
Sigma Aldrich, Mumbai, India. All other chemicals used were of 
analytical grade and purchased from Loba Chemie, Mumbai, India.
Purification of gum [14]
First, the foreign extraneous matter such as bark was physically 
separated from kondagogu gum, then powdered using mixer grinder, 
and passed through sieve #80. The powdered gum was dispersed in 
distilled water using a magnetic stirrer to get a 1% solution, which 
is kept in sonicator for 10 min until it was clear and then added to 
equimolar mixture of acetone and ethanol (2:1 v/v) to get precipitation 
of gum. Precipitated polymer was kept in an oven at 40°C for drying, 
powdered, and then used for further studies.
Preparation of transdermal patch [23]
Matrix-type transdermal patches of repaglinide were prepared using 
solvent casting method (Table 1). Required quantity of polymers, 
HPMC K4M, and kondagogu gum was accurately weighed and 
dispersed in water using a magnetic stirrer. The required quantity 
of drug was dissolved in 5 mL of methanol and added to the polymer 
solution. To the above mixture, polyethylene glycol 400 (20% w/w of 
total polymer) as plasticizer and propylene glycol (15% w/w of total 
polymer) as permeation enhancer were added. The resulted uniform 
solution was cast on the Petri dish and dried at room temperature 
for 24 h. The dried films were cut into required size, wrapped in 
aluminum foil, and kept in a desiccator containing a saturated 
solution of CaCl2 as a desiccant (29% RH) at room temperature 
(32°C) until use.
Mechanical properties [24]
Mechanical properties such as tensile strength and percentage 
elongation at break of the prepared transdermal films were measured 
as per ASTM D 685 using Universal Testing Machine (Instron 4309). 
A minimum of three samples were tested for each composition, and 
the average value was recorded. The thickness of the dry films was 
measured using microprocessor coating thickness gauze (Quint 
sonic, Mumbai, India). Thickness of the patch was measured at three 
different places, and the mean value was calculated. Six films (2.5 cm2) 
from each batch were randomly selected for weight variation. Films 
were weighed individually, and then the average weight was measured. 
The difference between individual and average weight indicated the 
weight variation.
Folding endurance [25]
A strip of film of specific surface area (3 cm × 2 cm) was cut and folded 
repeatedly at one place till it broke. The number of times the film was 
folded before breaking at the same place represented folding endurance 
for the formulation.
Drug content analysis [26]
For drug content analysis, films of known area (2.5 cm × 2.5 cm) 
were taken in 10 mL of volumetric flask and casting solvent mixture 
was added to it. The flasks were shaken in a water bath at 37°C for 
2 h, filtered through Whatman filter paper No. 1, and suitably diluted 
before drug content measurement using ultraviolet (UV)-visible 
spectrophotometer (UV-1800, SHIMADZU, Japan) at 241 nm.
Moisture content [27]
The films of repaglinide were weighed individually and kept in a 
desiccator containing a saturated solution of CaCl2 (29% of relative 
humidity) at room temperature (32°C) for 24 h. Subsequently, the films 
were weighed intermittently until a constant weight was achieved. The 
percentage of moisture uptake was calculated based on the difference 
between final and initial weight divided by initial weight.
Moisture uptake [27]
The weighed films kept in a desiccator for 24 h at room temperature 
(32°C) were taken out and exposed to 75% relative humidity (saturated 
solution of NaCl) until a constant weight was obtained. The percentage 
of moisture uptake was calculated as the difference between final and 
initial weight divided by initial weight.
Water vapor permeability (WVP) [28]
For WVP measurement, glass test tubes of 25 mL capacity were taken 
and filled with 20 mL of distilled water. The weight of each filled test 
tube was measured 1 h before closing the openings of glass test tubes 
by films. The area available for vapor permeation was 2.54 cm2, and all 
the containers were maintained at constant room temperature (32°C) 
for 24 h. The final weight was calculated after 1 h, and the WVP was 
calculated using the following equation:
WVP = W/A
Where W is the mean loss in weight (g) of the containers and A (m2) is 
the area of the exposed surface.
Fourier-transform infrared (FTIR) spectrophotometry [20,22]
To evaluate the integrity and compatibility of repaglinide with the 
carrier polymers and the excipients used in the polymer-drug matrix 
formulations, IR spectra of the drug and its optimized formulation were 
obtained by FTIR spectrophotometer (Perkin–Elmer-1000, Japan), 
using a potassium bromide pellet method.
Differential scanning calorimetry (DSC) [27]
All dynamic DSC studies were carried out using DuPont thermal 
analyzer with 2010 DSC Q 200, module. The instrument was calibrated 





HPMCK4M (mg) Kondagogu gum (mg) Polyethylene glycol 400 (% w/w) Propylene glycol (% w/w)
F1 200 1000 - 20 15
F2 200 900 100 20 15
F3 200 800 200 20 15
F4 200 700 300 20 15
F5 200 600 400 20 15
F6 200 500 500 20 15
HPMC: Hydroxypropyl methyl cellulose
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before testing using high purity indium metal as standard and the scans 
of the samples were recorded in the temperature range 0–300°C under 
nitrogen gas purge at a heating rate of 10°C/min.
In vitro release studies [24,27]
The in vitro release of drug from the prepared transdermal films was 
carried out using vertical type of Franz diffusion cell with a receptor 
compartment capacity of 22 mL. The jacketed diffusion cell with inlet 
and exit port for the circulation of water was used to maintain medium 
temperature at 32±0.5°C. A film specimen of surface area 2.5 cm2 
equivalent to 15 mg of the drug was placed on 0.22-lm cellulose acetate 
membrane which was previously equilibrated by soaking in phosphate 
buffer pH 7.4 for 24 h. The above medium was used to ensure the 
sink condition and stability of the drug. The membrane having 
film on it was immediately placed between the donor and receptor 
compartment and subsequently secured firmly by a stainless steel clip. 
The receptor compartment was stirred at 200 rpm with a teflon-coated 
magnetic bead. Aliquots of 0.5 mL were withdrawn from the receptor 
compartment at specified time intervals (0, 2, 4, 8, 12, 16, 20, and 
24 h) and replaced with equal volumes of fresh buffer maintained at 
the same temperature. The samples were filtered and analyzed using a 
UV- Spectrophotometer (Shimadzu 1602, Japan) at 241 nm.
Stability of the transdermal films [22,28]
Stability studies of the optimized formulation of prepared repaglinide 
transdermal film were carried out to determine the effect of 
formulation additives on the stability of the drug and also to determine 
the physical stability of the formulation. The optimized formulation 
was subjected to stability studies according to the ICH guidelines by 
storing at 25±2°C/60±5% RH and 30±2°C/65±5% RH for 12 months 
and 40±2°C/75±5% RH for 6 months (Thermolab, Mumbai, India). The 
samples were analyzed and checked for changes in physical appearance 
and drug content at regular intervals.
RESULTS AND DISCUSSION
All formulations were prepared by solvent casting method using 
water and methanol as solvent system. The repaglinide-loaded films 
were slightly opaque, having smooth surface and elegant appearance. 
The physicochemical properties of the films are given in Table 2. 
The thickness of the films found between 273 and 239 µm. As the 
concentration of KG was increased in the formulation, the thickness 
of the film decreased. This can be attributed to the high density of KG 
compared to HPMC K4M. The weight of the films varied from 71.8 to 
77.4 mg, indicating that different proportion of KG has shown little or 
no significant impact on weight variation.
The main aim of the folding endurance study on transdermal films is 
to test the ability of the film to endure stress-based rupture during the 
application and use. The folding endurance values for the repaglinide 
films ranged from 240.9±8.7 to 218.3±9.9. This result clearly indicates 
that the repaglinide films are having optimum flexibility and are not 
brittle. However, it is clear that as the concentration of KG increased, 
the folding endurance decreased. This can be attributed to the 
complex structure and friable nature of KG. The higher values obtained 
demonstrated that films would maintain the integrity and shape with 
the natural folding of the skin when applied on it.
The drug content data were indicated good content uniformity with 
low standard deviation. This indicates that the films of repaglinide 
with HPMC K4M and KG can be prepared with a higher degree of 
reproducibility.
The mechanical properties such as tensile strength and % elongation 
at break of all the repaglinide films were measured, and the data are 
shown in Table 2. A hard and tough polymeric film, generated from high 
values of both the studies, is always desired as it has qualities suited 
best as a drug delivery system for application on the skin. This implies 
that higher tensile strength values prevent abrasion of the film caused 
by contact with patient clothing, whereas higher % elongation at 
break values allows the free movement of film on skin contact without 
breaking. The % elongation at break values ranged from 43±3.7 to 
31±4.1 indicating good flexibility. It is clear that as the concentration 
of HPMC K4M increased, the value also increased. The tensile strength 
of the repaglinide films varied from 0.38±0.017 to 0.53±0.016 kg/cm2. 
The tensile strength values increased with increase in the concentration 
of KG in the film. This increase in value indicates that more force is 
required to deform the formulations having a high concentration of KG 
compared to HPMC K4M alone.
The moisture absorption is a tool to indicate how the film would behave 
during the initial stage of drug release. The lower moisture content in 
the formulations helps them to remain stable and become a completely 
dried and brittle film. Again, low moisture uptake protects the material 
from microbial contamination and bulkiness. The results of moisture 
content and moisture absorption studies are shown in Fig. 1a. The 
moisture content and % moisture uptake in the repaglinide films 
ranged from 6.5 to 11.2 and 11.4% to 33.4%, respectively, indicating 
that the values increased slightly due to increase of KG concentration 
in the films. This can be attributed to the hydrophilic nature of KG. The 
WVP values of the repaglinide films are shown in Fig. 1b. All the WVP 
values were found to be ranging between 632.17 and 573.74 g/m2/day. 
The average transepidermal water loss by diffusion through the skin 
is 300–400 mL/day which corresponds to 157.894–210.526 g/m2/day 
(normal body surface area is 1.9 m2). The obtained values indicate that 
the repaglinide films were not occlusive in nature and thereby do not 
disturb natural process of water loss from body surface.
The FTIR spectra of pure drug repaglinide and formulation F4 are 
shown in Fig. 2. The FTIR spectra of repaglinide and its formulation 
were found to be identical. The characteristic IR absorption peaks of 
repaglinide at 3320 cm−1 (N-H stretching), 2947 cm−1 (C-H stretching), 
1728 cm−1 (C=O stretching), and 1460 cm−1 (C-H deformation) 
were obtained. The FTIR spectra of the pure drug, as well as drug 
incorporated formulation (F4), indicated that no chemical interaction 
occurred between the repaglinide and the polymers used. However, 
a slight change in absorption peaks position was noticed. This result 
clearly indicates that the drug and polymers used are compatible.
DSC thermograms of the pure drug and prepared formulation were 
recorded and shown in Fig. 3. From Fig. 3, it is clear that a sharp 
endothermic peak at 131°C was obtained for pure repaglinide. The 
melting point of repaglinide has not been seen in the prepared 
transdermal film, indicating that the drug has dispersed in micron level 
in the prepared films.
Table 2: Physicochemical properties of repaglinide transdermal films
Formulation 
code






% Elongation at 
break
Tensile strength  
(kg/cm2) 
F1 273±4.3 71.82±2.16 240.9±8.78 15.3±0.65 43±3.7 0.38±0.017
F2 269±3.6 72.29±1.92 236.4±7.39 15.9±0.46 41±3.6 0.39±0.014
F3 262±3.9 73.25±1.57 229.8±7.27 14.5±0.61 38±3.2 0.42±0.018
F4 257±4.1 74.04±1.24 225.2±9.75 15.4±0.53 37±3.9 0.46±0.012
F5 246±2.8 76.92±1.64 221.7±8.82 15.2±0.52 33±3.4 0.49±0.015
F6 239±3.5 77.41±1.53 218.3±9.94 14.6±0.68 31±4.1 0.53±0.016
Mean±SD, n=6
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formulation increased, the drug release from the transdermal film 
decreased. From Fig. 4, it is observed that the formulations F1-F3 have 
released 88.6, 81.3, and 74.1% of the drug within 12 h of the study 
period. Formulations F1 and F2 have released entire 100% drug by 
20 h, whereas formulation F6 has released only 89.5% of drug in 20 h 
study period, indicating that they are not suitable for the present study. 
Formulations F3, F4, and F5 have released 99.1, 94.7, and 91.3% of 
loaded drug indicating their suitability for 24 h drug release.
In vitro release study data of formulations F3, F4, and F5 were fitted 
into various mathematical models to determine the best-fit model. 
The best-fit model with the highest regression coefficients (R2) for all 
the formulations is given in Table 3, and the best-fit model was found 
to be Higuchi model. To know the type of diffusion, all data were fitted 
to Korsmeyer–Peppas equation. The release exponent values (n=0.558–
0.623) demonstrated anomalous diffusion (non-Fickian model), i.e., the 
release mechanism followed the combination of diffusion and swelling. 
This is attributed to the presence of swelling polymers HPMC K4M and 
KG in the matrix. From Table 3, it was concluded that formulation F4 with 
R2 value of 0.9987 is the optimized formulation for 24 h study period.
Stability studies of the optimized repaglinide film were performed to 
ascertain if the drug undergoes any degradation during its shelf life. 
The drug release characteristics of the formulation were studied in 
in vitro conditions by using artificial semi-permeable membrane. The 
drug release profiles of the repaglinide films are shown graphically 
in Fig. 4. From Fig. 4, it is clear that as the concentration of KG in the 
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In the present study, the optimized formulation F4 was selected for 
stability studies. The obtained results of stability studies are given in 
Table 4. From Table 4, it can be concluded that the repaglinide is stable 
in the optimized formulation for the study period.
CONCLUSION
Repaglinide films were prepared by solvent casting method. The FTIR 
spectra of the pure drug, as well as drug incorporated formulation, 
indicated that no chemical interaction occurred between repaglinide 
and the polymers/excipients used. DSC thermograms of the pure drug 
and prepared formulation inferred that the drug has dispersed in micron 
level in the films. In vitro release study data of prepared formulations 
were fitted into various mathematical models and the best-fit model 
was found to be Higuchi model. It was concluded that formulation F4 
with R2 value of 0.9987 is the optimized formulation for 24 hr study 
period. Stability studies of the drug formulations proved that the drug 
was stable in the optimized transdermal film formulation for the study 
period. Therefore, it can be concluded that the prepared film has the 
potential for transdermal drug delivery of repaglinide with improved 
permeation profile for longer period of time, thereby increasing the 
patient compliance.
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